Contineum Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Contineum Therapeutics (CTNM).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingOutperform# Analysts5Avg. Consensus PT$22Upside to Avg. PT+68.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 28, 2026	Morgan Stanley	Jeffrey Hung	PT Cut	Equal-Weight	$18→$17
Sep 15, 2026	Jones Trading	Debanjana Chatterjee	PT Cut	Buy	$26→$24
Sep 15, 2026	Baird	Joel Beatty	PT Cut	Outperform	$20→$19
Jul 31, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$22→$23
May 14, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$14→$16
Mar 6, 2026	Baird	Joel Beatty	PT Raise	Outperform	$14→$20
Jan 8, 2026	Morgan Stanley	Jeffrey Hung	Downgrade	Overweight→Equal-Weight	$23→$14
Nov 24, 2025	Baird	Joel Beatty	PT Cut	Outperform	$16→$14
Nov 21, 2025	RBC Capital	Brian Abrahams	PT Cut	Outperform	$25→$22
Sep 25, 2025	Leerink Partners	Faisal Khurshid	Initiate	Outperform	$20
Aug 18, 2025	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$20→$21
May 19, 2025	Morgan Stanley	Jeffrey Hung	PT Cut	Overweight	$25→$20
May 15, 2025	RBC Capital	Brian Abrahams	Maintained	Outperform	$31
Mar 13, 2025	Jones Trading	Debanjana Chatterjee	Initiate	Buy	$23
Mar 7, 2025	Morgan Stanley	Jeffrey Hung	Assumes	Overweight	$25
Mar 7, 2025	Baird	Joel Beatty	PT Cut	Outperform	$32→$16
Jan 9, 2025	RBC Capital	Brian Abrahams	Maintained	Outperform	$31
Nov 7, 2024	RBC Capital	Brian Abrahams	PT Cut	Outperform	$32→$31
Oct 22, 2024	Baird	Joel Beatty	Initiate	Outperform	$32
Aug 14, 2024	RBC Capital	Brian Abrahams	PT Raise	Outperform	$30→$32

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Lowers Price Target to $17

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Equal-Weight and lowers the price target from $18 to $17.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $19

Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from $20 to $19.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23

RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and raises the price target from $22 to $23.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Equal-Weight and raises the price target from $14 to $16.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Contineum Therapeutics, Raises Price Target to $20

Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and raises the price target from $14 to $20.

Benzinga Newsdesk

PRO
Morgan Stanley Downgrades Contineum Therapeutics to Equal-Weight, Lowers Price Target to $14

Morgan Stanley analyst Jeffrey Hung downgrades Contineum Therapeutics (NASDAQ:CTNM) from Overweight to Equal-Weight and lowers the price target from $23 to $14.

Benzinga Newsdesk

Contineum Therapeutics Inc

Contineum Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Lowers Price Target to $17

PRO
Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $19

PRO
RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23

PRO
Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16

PRO
Baird Maintains Outperform on Contineum Therapeutics, Raises Price Target to $20

PRO
Morgan Stanley Downgrades Contineum Therapeutics to Equal-Weight, Lowers Price Target to $14

People Also Watch

People Also Watch

Contineum Therapeutics Inc

Contineum Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Lowers Price Target to $17

PROBaird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $19

PRORBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23

PROMorgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16

PROBaird Maintains Outperform on Contineum Therapeutics, Raises Price Target to $20

PROMorgan Stanley Downgrades Contineum Therapeutics to Equal-Weight, Lowers Price Target to $14

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Lowers Price Target to $17

PRO
Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $19

PRO
RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23

PRO
Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16

PRO
Baird Maintains Outperform on Contineum Therapeutics, Raises Price Target to $20

PRO
Morgan Stanley Downgrades Contineum Therapeutics to Equal-Weight, Lowers Price Target to $14